Compare EQH & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQH | PRAX |
|---|---|---|
| Founded | 1859 | 2015 |
| Country | United States | United States |
| Employees | 8000 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 9.6B |
| IPO Year | N/A | 2020 |
| Metric | EQH | PRAX |
|---|---|---|
| Price | $38.18 | $295.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | $60.80 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 2.8M | 331.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $43.41 | N/A |
| Revenue Next Year | $7.61 | $6,395.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.51 | $26.70 |
| 52 Week High | $56.61 | $354.87 |
| Indicator | EQH | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 30.88 | 36.94 |
| Support Level | N/A | $290.36 |
| Resistance Level | $55.05 | $322.32 |
| Average True Range (ATR) | 1.69 | 18.62 |
| MACD | -0.28 | -5.97 |
| Stochastic Oscillator | 7.65 | 2.53 |
Equitable Holdings Inc is a financial services company providing retirement, asset management, and wealth management solutions for individual and institutional clients, operating through three segments. The Retirement segment generates the majority of revenue and offers annuities, retirement savings plans, institutional savings products, and includes the spread lending business. The Asset Management segment provides diversified investment management and related services globally through Institutional, Retail, and Private Wealth channels and reflects the business of AB. The Wealth Management segment offers advisory accounts, financial planning and advice, life insurance, and annuity products. Revenues are earned predominantly from fee income, income from investments, and insurance premiums.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.